By Maitane Sardon

Roche said that the European Commission, the EU's executive arm, has approved extending the use of its Evrysdi treatment for babies under two months diagnosed with spinal muscular atrophy.

The Swiss pharma company said Tuesday that the approval is based on interim data from an ongoing trial that showed most babies treated with Evrysdi were able to stand and walk within timeframes typical of healthy babies by 12 months of treatment, Roche said.

Evrysdi is currently approved in the EU for treating patients two months or older.

Write to Maitane Sardon at maitane.sardon@wsj.com

(END) Dow Jones Newswires

August 29, 2023 01:37 ET (05:37 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Roche (QX) Charts.